Janssen Pharmaceutica Nv

Taraneh Mirzadegan

James Patrick Edwards

Cheryl A Grice

Laurent Gomez

Wendy Eccles

Scott D Bembenek

Aaron M Kearney

Adrienne M Landry-Bayle

Kelly J McClure

Genesis M Bacani

Alejandro Santillán, Jr

Alice Lee-Dutra

David A Kummer

Ronald L Wolin

Aihua Wang

Hariharan Venkatesan

Kevin Douglas Kreutter

Kristi A Leonard

Maud J Urbanski

Xiaohua Xue

Anne Fourie

Rachel T Nishimura

Craig R Woods

Umar Maharoof

Kent Barbay

Kelly Ganamet

Matthew T Epperson

Alexandro Santillán, Jr

Alejandro Santillan

Kelly J Mcclure

Kelly Lynn Ganamet

The present invention comprises compounds of Formula I. wherein: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

Phenyl linked quinolinyl modulators of ROR&#x3b3;t

Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene Ahydrolase (LTAH or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTAH activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

[object Object]

Aryl-substituted bridged or fused diamines as modulators of leukotriene  A ydrolase

Growing community of inventors

San Diego, CA, United States of America

Taraneh Mirzadegan